Cytopenias posttransplant
| Age, y . | Sex . | Cytopenia . | Treatment and outcome . |
|---|---|---|---|
| 21 | M | Warm type AIHA | Prednisolone, rituximab, splenectomy, NR; died GVHD and thromboembolism |
| 43 | F | Warm type AIHA | Prednisolone NR, rituximab, CR |
| 30 | F | Warm type AIHA | Prednisolone NR, rituximab CR |
| 37 | M | Warm type AIHA | Prednisolone relapsed, rituximab CR |
| 22 | F | Immune thrombocytopenia purpura | No treatment required |
| 63 | M | Probable autoimmune neutropenia | Responded to GCSF, resolved |
| 57 | F | Dapsone induced pancytopenia | Resolved on drug withdrawal |
| 18 | F | MMF induced neutropenia | Resolved on drug withdrawal |
| 65 | F | Ganciclovir induced cytopenias, hemophagocytic syndrome | CMV specific CTLs; prednisolone, IVIg, romiplostim; transfusion dependent, hypocellular BM |
| 58 | F | Poor engraftment, hypocellular BM | FBC slowly improved with increased CSA dose; current status, transfusion independent, Hb 103 g/L, neutrophils 2.1 × 109/L, platelets 48 × 109/L, PB CD15 100%, CD3 23% |
| 27 | F | Thrombocytopenia (platelet count 86 × 109/L) month +50; BM reduced megakaryocytes, CD15 61%, CD3 86% | Responded to ciclosporin reintroduction |
| Age, y . | Sex . | Cytopenia . | Treatment and outcome . |
|---|---|---|---|
| 21 | M | Warm type AIHA | Prednisolone, rituximab, splenectomy, NR; died GVHD and thromboembolism |
| 43 | F | Warm type AIHA | Prednisolone NR, rituximab, CR |
| 30 | F | Warm type AIHA | Prednisolone NR, rituximab CR |
| 37 | M | Warm type AIHA | Prednisolone relapsed, rituximab CR |
| 22 | F | Immune thrombocytopenia purpura | No treatment required |
| 63 | M | Probable autoimmune neutropenia | Responded to GCSF, resolved |
| 57 | F | Dapsone induced pancytopenia | Resolved on drug withdrawal |
| 18 | F | MMF induced neutropenia | Resolved on drug withdrawal |
| 65 | F | Ganciclovir induced cytopenias, hemophagocytic syndrome | CMV specific CTLs; prednisolone, IVIg, romiplostim; transfusion dependent, hypocellular BM |
| 58 | F | Poor engraftment, hypocellular BM | FBC slowly improved with increased CSA dose; current status, transfusion independent, Hb 103 g/L, neutrophils 2.1 × 109/L, platelets 48 × 109/L, PB CD15 100%, CD3 23% |
| 27 | F | Thrombocytopenia (platelet count 86 × 109/L) month +50; BM reduced megakaryocytes, CD15 61%, CD3 86% | Responded to ciclosporin reintroduction |
CR, complete response; CTLs, cytotoxic T lymphocytes; IVIg, intravenous immunoglobulin; NR, no response.